The Turkish Notified Body TSE is no longer designated for the In-Vitro Diagnostic Device Directive 98/79/EC since mid of October. Until now, neither the European Commission nor TSE provided reasons for the suspension of the designation.
The Medical Device Coordination group recently published the “Guidance on Classification Rules for in vitro Diagnostic Medical Devices under Regulation (EU) 2017/746”. In this guidance the underlaying definitions and principles of the classification scheme are explained, and each classification rule is analyzed and rationalized. A must read for all manufacturers of IVDs.
The FDA published a draft guidance on the electromagnetic compatibility of medical devices. The guidance addresses the contents that are required for premarket submissions. Although the IEC 60601-1-2 was a recognized consensus standard before, the new draft guidance provides more details towards other emitting devices and their possible ranges of disturbance and thus might alter the testing scope relate to EMC testing.
Among other new guidance’s, a new guidance for “Regulatory Considerations for Microneedling Products” was published. It helps to understand when devices using needles are considered medical device and would hence be required to be marketed as such.
The department of health-Medical Device Division has issued two FAQ brochures on Medical devices and In-Vitro Diagnostic devices. The two FAQ documents briefly describe which products are considered medical devices and the classification of devices.
The Therapeutic Goods Administration (TGA) has changed the name of the Clinical Trial Exemption (CTX) scheme to the Clinical Trial Approval (CTA) scheme. The name change from CTX to CTA more accurately reflects the nature of the scheme under the Therapeutic Goods Act 1989, which involves sponsors applying for the TGA's approval to supply unapproved therapeutic goods in Australia via a clinical trial despite the therapeutic goods are not being entered in the Australian Register of Therapeutic Goods (ARTG). The scheme's previous name of CTX underscored the exemption given by the TGA to a sponsor from entering their therapeutic good in the ARTG before conducting a clinical trial.
You can download all Regulatory Affairs Updates compiled for you as a PDF under the following link.